36
Participants
Start Date
October 16, 2019
Primary Completion Date
March 28, 2023
Study Completion Date
November 29, 2023
Crizanlizumab
Crizanlizumab is a concentrate for solution for infusion, IV use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
Montefiore Medical Center, The Bronx
Childrens National Hospital, Washington D.C.
Duke University Medical Center, Durham
Brody School of Medicine, Greenville
Prisma Health Upstate, Greenville
Emory University School of Medicine, Atlanta
Foundation for Sickle Cell Disease Research, Hollywood
University Of Alabama, Birmingham
LSU Medical Center, Shreveport
University of Texas Medical School, Houston
University of Connecticut Health Center, Farmington
Childrens Hosp Boston Dept of Hematology, Boston
University of Pittsburgh, Pittsburgh
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY